What are the key considerations for deciding on the use of CAR T-cell therapy for patients with follicular lymphoma?

Click to increase image sizeClick to decrease image size

Declaration of interest

B Hunter has received honoraria from AbbVie, ADC Therapeutics, Bristol Myers Squibb, Genmab, Janssen, Kite Pharma, Notable Labs, Novartis, and has received speaker’s fees from Kite Pharma. Added two companies and now it is correct.

B Hunter has received honoraria from AbbVie, ADC Therapeutics, Bristol Myers Squibb, Genmab, Janssen, Kite Pharma, Notable Labs, Novartis, and has received speaker’s fees from Kite Pharma. Added two companies and now it is correct.

Reviewer disclosures

Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.

Additional information

Funding

This paper received no funding.